The DOI matches its Crossref record; 302 of the 305 references it cites were found in a registry or an index.
Clinical Practice Guidelines for the Management Candidiasis: 2009 Update by the Infectious Diseases Society of America
Open accessAbstract
Guidelines for the management of patients with invasive candidiasis and mucosal candidiasis were prepared by an Expert Panel of the Infectious Diseases Society of America. These updated guidelines replace the previous guidelines published in the 15 January 2004 issue of Clinical Infectious Diseases and are intended for use by health care providers who care for patients who either have or are at risk of these infections. Since 2004, several new antifungal agents have become available, and several new studies have been published relating to the treatment of candidemia, other forms of invasive candidiasis, and mucosal disease, including oropharyngeal and esophageal candidiasis. There are also recent prospective data on the prevention of invasive candidiasis in high-risk neonates and adults and on the empiric treatment of suspected invasive candidiasis in adults. This new information is incorporated into this revised document.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“In contrast with the 2009 Infectious Disease Society of America guidelines for the treatment of invasive candidiasis, in which echinocandins were recommended only for neutropenic patients and patients with previous exposure to antifungals (64)”
From Population-Based Active Surveillance for Culture-Confirmed Candidemia — Four Sites, United States, 2012–2016 (2019) · cites this paper as [64]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredIn the citing paper
“Consensus guidelines do suggest a combination of amphotericin B and flucytosine for some infection types such as Candida meningitis, endophthalmitis, and endocarditis.”
From Fungal Sepsis: Optimizing Antifungal Therapy in the Critical Care Setting (2011) · cites this paper as [110]
In the citing paper
“The IDSA guideline for invasive candidiasis recommends a 2-week treatment duration following clearance of Candida from the bloodstream and resolution of symptoms attributable to candidemia.”
From Fungal Sepsis: Optimizing Antifungal Therapy in the Critical Care Setting (2011) · cites this paper as [110]
In the citing paper
“Longer durations are recommended for persistent candidemia and for metastatic infection involving other sites (ie, CNS, bone, endocarditis, joint/ prosthetic joint infection).”
From Fungal Sepsis: Optimizing Antifungal Therapy in the Critical Care Setting (2011) · cites this paper as [110]
In the citing paper
“Treatment guidelines recommend step down to fluconazole for patients who have improved clinically after initial therapy with an echinocandin or amphotericin B and who are infected with an organism that is likely to be susceptible to fluconazole (eg, C albicans, C parapsilosis, and C tropicalis) or if there is documented susceptibility based on laboratory MIC testing.”
From Fungal Sepsis: Optimizing Antifungal Therapy in the Critical Care Setting (2011) · cites this paper as [110]
In the citing paper
“Therefore, the current guidelines suggest ophthalmologic examination for every patient with candidemia.”
From Fungal Sepsis: Optimizing Antifungal Therapy in the Critical Care Setting (2011) · cites this paper as [110]
In the citing paper
“Venous catheter infection and IC guidelines, including the current IDSA guidelines, recommend removal of any intravascular catheter that is positive for a fungal pathogen (ie, Candida) based on evidence from large retrospective and observational studies.”
From Fungal Sepsis: Optimizing Antifungal Therapy in the Critical Care Setting (2011) · cites this paper as [110]
In the citing paper
“Thus, the American Society of Infectious Diseases recommends that patients should use topical and oral azoles concurrently [38].”
From Treatment of Vulvovaginal Candidiasis—An Overview of Guidelines and the Latest Treatment Methods (2023) · cites this paper as [38]
In the citing paper
“They display in vitro fungicidal activity against most Candida species, attractive tolerability and pharmacokinetic profiles, and have been recommended as first line agents for invasive candidiasis (1–6).”
From Echinocandin resistance: an emerging clinical problem? (2014) · cites this paper as [6]
In the citing paper
“They display in vitro fungicidal activity against most Candida species, attractive tolerability and pharmacokinetic profiles, and have been recommended as first line agents for invasive candidiasis (1–6).”
From Echinocandin resistance: an emerging clinical problem? (2014) · cites this paper as [6]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wisplinghoff, H., Bischoff, T., Tallent, S. M., Seifert, H., Wenzel, R. P., & Edmond, M. B. (2004) · Clinical Infectious Diseases · doi:10.1086/421946 · Cited by 4,496
Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem
Pfaller, M. A., & Diekema, D. J. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-06 · Cited by 4,174 · cited 2×
“krusei [26, 81], but”
2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer
Hughes, W. T., Armstrong, D., Bodey, G. P., Bow, E. J., Brown, A. E., Calandra, T., Feld, R., Pizzo, P. A., Rolston, K. V. I., Shenep, J. L., et al. (2002) · Clinical Infectious Diseases · doi:10.1086/339215 · Cited by 1,964
Self-citationPosaconazole vs. Fluconazole or Itraconazole Prophylaxis in Patients with Neutropenia
Cornely, O. A., Maertens, J. A., Winston, D. J., Perfect, J. R., Ullmann, A. J., Walsh, T. J., HELFGOTT, D. C., Hołowiecki, J., Stockelberg, D., Goh, Y. T., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa061094 · Cited by 1,802
Self-citationComparison of Caspofungin and Amphotericin B for Invasive Candidiasis
Mora-Duarte, J., Betts, R., Rotstein, C., Colombo, A. L., Thompson-Moya, L., Smietana, J., Lupinacci, R., Sable, C., Kartsonis, N., & Perfect, J. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021585 · Cited by 1,380
Posaconazole or Fluconazole for Prophylaxis in Severe Graft-versus-Host Disease
Ullmann, A. J., Lipton, J. H., Vesole, D. H., Chandrasekar, P. H., Langston, A. A., Tarantolo, S., Greinix, H., de Azevedo, W. M., Reddy, V. S., Boparai, N., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa061098 · Cited by 1,339
Morrell, M., Fraser, V. J., & Kollef, M. H. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.9.3640-3645.2005 · Cited by 1,286
Liposomal Amphotericin B for Empirical Therapy in Patients with Persistent Fever and Neutropenia
Walsh, T. J., Finberg, R. W., Arndt, C., Hiemenz, J., Schwartz, C., Bodensteiner, D., Pappas, P., Seibel, N., Greenberg, R. N., Dummer, S., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903113401004 · Cited by 1,205
Self-citationGarey, K. W., Rege, M., Pai, M. P., Mingo, D. E., Suda, K. J., Turpin, R. S., & Bearden, D. T. (2006) · Clinical Infectious Diseases · doi:10.1086/504810 · Cited by 1,171
Attributable Mortality of Nosocomial Candidemia, Revisited
Gudlaugsson, O., Gillespie, S., Lee, K., Berg, J. V., Hu, J., Messer, S., Herwaldt, L., Pfaller, M., & Diekema, D. (2003) · Clinical Infectious Diseases · doi:10.1086/378745 · Cited by 1,140
Flagged first, then by citations
3 of the 305 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 1,001–1,020 of 1,020
Candida glabrata : new tools and technologies—expanding the toolkit
Ho, H.-L., & Haynes, K. (2015) · FEMS Yeast Research · doi:10.1093/femsyr/fov066 · Cited by 29
Echinocandins: Addressing outstanding questions surrounding treatment of invasive fungal infections
Holt, S. L., & Drew, R. H. (2011) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp100456 · Cited by 26
Antifungal resistance does not necessarily affect Candida glabrata fitness
Borghi, E., Andreoni, S., Cirasola, D., Ricucci, V., Sciota, R., & Morace, G. (2014) · Journal of Chemotherapy · doi:10.1179/1973947813y.0000000100 · Cited by 25
Pan, Y., Sun, Y., Chen, L., Cheng, Y., Jin, P., Zhang, W., Zheng, L., Liu, J., Zhou, T., Xu, Z., et al. (2023) · Biofilm · doi:10.1016/j.bioflm.2023.100162 · Cited by 26
Designed Antimicrobial Peptides for Recurrent Vulvovaginal Candidiasis Treatment
Woodburn, K. W., Clemens, L. E., Jaynes, J., Joubert, L.-M., Botha, A., Nazik, H., & Stevens, D. A. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02690-18 · Cited by 25
Lewis, R. E., Liao, G., Hou, J., Prince, R. A., & Kontoyiannis, D. P. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr142 · Cited by 23
Firinu, D., Massidda, O., Lorrai, M. M., Serusi, L., Peralta, M., Barca, M. P., Serra, P., & Manconi, P. E. (2011) · Clinical and Developmental Immunology · doi:10.1155/2011/283239 · Cited by 23
Gold, J. A. W., Seagle, E. E., Nadle, J., Barter, D. M., Czaja, C. A., Johnston, H., Farley, M. M., Thomas, S., Harrison, L. H., Fischer, J., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab512 · Cited by 20
Hanadate, T., Wakasugi, M., Sogabe, K., Kobayashi, T., Horita, H., Kawamura, I., Matsui, K., Sou, M., Hori, Y., & Hoshino, Y. (2011) · Journal of Infection and Chemotherapy · doi:10.1007/s10156-011-0219-0 · Cited by 21
Kan, S., Song, N., Pang, Q., Mei, H., Zheng, H., Li, D., Cui, F., Lv, G., An, R., Li, P., et al. (2023) · Mycopathologia · doi:10.1007/s11046-022-00687-w · Cited by 21
Lum, L., Lee, A., Vu, M., Strasser, S., & Davis, R. (2020) · Transplant Infectious Disease · doi:10.1111/tid.13361 · Cited by 22
Effect of Statin Use on Outcomes of Adults with Candidemia
Cuervo, G., Garcia-Vidal, C., Nucci, M., Puchades, F., Fernández-Ruiz, M., Mykietiuk, A., Manzur, A., Gudiol, C., Pemán, J., Viasus, D., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0077317 · Cited by 20
Antifungal Activity of Plant Secondary Metabolites on Candida albicans: An Updated Review
Khan, A., Moni, S. S., Ali, M., Mohan, S., Jan, H., Rasool, S., Kamal, M. A., Alshahrani, S., Halawi, M., & Alhazmi, H. A. (2023) · Current Molecular Pharmacology · doi:10.2174/1874467215666220304143332 · Cited by 17
Sgherri, C., Porta, A., Castellano, S., Pinzino, C., Quartacci, M. F., & Calucci, L. (2014) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2013.10.015 · Cited by 16
Gizińska, M., Staniszewska, M., & Ochal, Z. (2018) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557518666180924121209 · Cited by 15
Treatment of invasive candidiasis: between guidelines and daily clinical practice
Tagliaferri, E., & Menichetti, F. (2015) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.2015.1029916 · Cited by 14
Smith, R. P., Baltch, A., Bopp, L. H., Ritz, W. J., & Michelsen, P. P. (2011) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2011.06.018 · Cited by 14
Ben-Ami, R., Hilerowicz, Y., Novikov, A., & Giladi, M. (2014) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2014.02.008 · Cited by 12
Trends of antifungal use based on sales data in Japan from 2006 to 2015
Kawabe, A., Muraki, Y., Inose, R., Kusama, Y., Goto, R., Ebisui, A., Ishii, S., Ishikane, M., Ohge, H., & Ohmagari, N. (2020) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b20-00302 · Cited by 9
Zhao, Q., Huang, X., Liu, Q., Cao, Y., Yu, X., Liu, Y., Hu, N., Han, Z., Tan, J., Li, X., et al. (2026) · Microbiology Spectrum · doi:10.1128/spectrum.01672-25
Metadata
- Authors
- Pappas, P. G., Kauffman, C. A., Andes, D., Benjamin, D. K., Calandra, T. F., Edwards, J. E., Filler, S. G., Fisher, J. F., Kullberg, B.-J., Zeichner, L. O., Reboli, A. C., Rex, J. H., Walsh, T. J., & Sobe, J. D.
- Affiliations
- University of Alabama at Birmingham (US)
- University of Michigan (US)
- University of Wisconsin–Madison (US)
- Duke Medical Center (US)
- Centre Hospitalier Universitaire Vaudois (CH)
- University of California, Los Angeles (US)
- Augusta University (US)
- Radboud University Nijmegen (NL)
- University of Texas at Houston, Houston
- Cooper University Hospital (US)
- AstraZeneca (United Kingdom) (GB)
- National Cancer Institute (US)
- Wayne State University (US)
- Corresponding author
- Pappas, Peter G.
- ORCID
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-03-01
- Volume
- 48
- Issue
- 5
- Pages
- 503-535
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- PMC
- PMC7294538
- OpenAlex
- W2150428940
- Cited by
- 3,191
- References
- 305
- Citations by year
- 2026: 23 · 2025: 41 · 2024: 49 · 2023: 55 · 2022: 65 · 2021: 121 · 2020: 155 · 2019: 149 · 2018: 149 · 2017: 195 · 2016: 226 · 2015: 327 · 2014: 312 · 2013: 311 · 2012: 319
- FWCI
- 230.85
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- SERVAL (Université de Lausanne) (publishedVersion, other-oa)
- PubMed Central (acceptedVersion)
- reroDoc Digital Library (submittedVersion)
- IRIS (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Funders
- Amgen
- Pfizer
- AstraZeneca
- Gilead Sciences
- Infectious Diseases Society of America
- Astellas Pharma
- Basilea Pharmaceutica
- National Institutes of Health
- Centers for Disease Control and Prevention
- Pfizer Pharmaceuticals
- National Cancer Institute (Z01SC006830)
- National Institute of Child Health and Human Development
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Health Sciences › Medicine › Ophthalmology › Ocular Infections and Treatments
- Keywords
- invasive candidiasis, mucosal candidiasis, candidemia, oropharyngeal candidiasis, esophageal candidiasis, antifungal agents, empirical antifungal therapy, high-risk infants, high-risk adults
- MeSH terms
- Antifungal Agents, Candidiasis, Humans
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
